Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer - Seite 2
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding future plans or expectations for the Mutation-Allostery-Pharmacology platform and the continued development and advancement of the Company’s
pipeline. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking
statements include: the success, cost, and timing of the Company’s product candidate development activities and planned clinical trials, the Company’s ability to execute on its strategy, regulatory
developments in the United States, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and
operations, as well as those risks and uncertainties set forth in its 2019 annual report on Form 10-K filed with the United States Securities and Exchange Commission and its other filings filed
with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts:
For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com
Lesen Sie auch
For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com